Chicago—Biosimilars for oncology are gaining ground, with more payors implementing strategies to cover them and large projected savings for health plans, health systems and patients, speakers said during a panel discussion at the AMCP 2022 annual meeting.
Biosimilars are defined as biologic products approved by the FDA that are highly similar to an FDA-approved biologic product, also known as the reference product, said YuQian Liu, PharmD, RPh, the director of specialty